Digoxin therapy is not associated with improved survival in epithelial ovarian cancer: A SEER-Medicare database analysis
- 1 February 2016
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 140 (2) , 285-288
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Cancer StatisticsJAMA, 2013
- Cardiac glycosides in cancer therapy: from preclinical investigations towards clinical trialsInvestigational New Drugs, 2013
- Assembling the puzzle of anti-cancer mechanisms triggered by cardiac glycosidesMitochondrion, 2013
- A Novel Two-Stage, Transdisciplinary Study Identifies Digoxin as a Possible Drug for Prostate Cancer TreatmentCancer Discovery, 2011
- The Sodium Pump α1 Subunit as a Potential Target to Combat Apoptosis-Resistant GlioblastomasNeoplasia, 2008
- The α1 subunit of the sodium pump could represent a novel target to combat non‐small cell lung cancersThe Journal of Pathology, 2007
- Intraperitoneal Cisplatin and Paclitaxel in Ovarian CancerNew England Journal of Medicine, 2006
- Impact of Adjuvant Chemotherapy and Surgical Staging in Early-Stage Ovarian Carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm TrialJNCI: Journal of the National Cancer Institute, 2003
- Digitoxin medication and cancer; case control and internal dose-response studiesBMC Cancer, 2001
- Digitoxin is a potential anticancer agent for several types of cancerMedical Hypotheses, 1999